In the SURPASS-2 study, TZP at the dose of 5, 10, and 15 mg were compared to the GLP-1RA semaglutide (1 mg once weekly) in patients not well controlled in therapy only with metformin (44, 71)
patients on the potential effects of GLP1R agonists on the cardiovascular system
In a separate 2 year double blinded, placebo-controlled study, weekly subcutaneous injections of semaglutide (2.4mg) in obese patients, average body weights decreased 12.6% over placebo at the 2-year point [23]
& Ohashi, P
With millions of people now taking GLP-1 medications for weight loss and diabetes, you might notice changes in friends, family members or coworkers and wonder if they are using these drugs
This follows their publication at ADA and reflect important progress in the Beyond A1C and Time-in-Range movements